|
US20030114503A1
(en)
*
|
1997-06-16 |
2003-06-19 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
|
|
HRP20000904A2
(en)
*
|
1998-07-06 |
2001-12-31 |
Janssen Pharmaceutica Nv |
Farnesyl protein transferase inhibitors for treating arthropathies
|
|
IL141239A0
(en)
*
|
1998-08-27 |
2002-03-10 |
Pfizer Prod Inc |
Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
|
|
DE69923849T2
(de)
*
|
1998-08-27 |
2006-01-12 |
Pfizer Products Inc., Groton |
Quinolin-2-on-derivate verwendbar als antikrebsmittel
|
|
TR200201296T2
(tr)
|
1999-02-11 |
2002-07-22 |
Pfizer Products Inc. |
Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
|
|
HN2000000266A
(es)
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
|
EP1267848B1
(en)
|
2000-02-24 |
2007-10-17 |
Janssen Pharmaceutica N.V. |
Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
|
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
|
US7196094B2
(en)
|
2000-09-25 |
2007-03-27 |
Janssen Pharmaceutica, N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
|
|
US7053105B2
(en)
|
2000-09-25 |
2006-05-30 |
Janssen Pharmaceutica, N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
|
AU2001293829A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
|
|
US7067531B2
(en)
|
2000-09-25 |
2006-06-27 |
Angibaud Patrick Rene |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
|
DE60139080D1
(de)
|
2000-11-21 |
2009-08-06 |
Janssen Pharmaceutica Nv |
Farnesyltransferase hemmende benzoheterocyclische derivate
|
|
WO2002050058A1
(en)
*
|
2000-12-19 |
2002-06-27 |
Pfizer Products Inc. |
Crystal forms of 6-[(4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl] -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
|
|
DE60117847T2
(de)
*
|
2000-12-27 |
2006-11-16 |
Janssen Pharmaceutica N.V. |
Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
|
|
WO2002056884A2
(en)
*
|
2001-01-22 |
2002-07-25 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
|
PL208238B1
(pl)
*
|
2001-03-12 |
2011-04-29 |
Janssen Pharmaceutica Nv |
Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
|
|
US20020151563A1
(en)
*
|
2001-03-29 |
2002-10-17 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
|
|
AU2002257114A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Schering Corporation |
Treatment of malaria with farsenyl protein transferase inhibitors
|
|
US20050165053A1
(en)
*
|
2001-06-04 |
2005-07-28 |
Cytovia, Inc. |
Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
US6713462B2
(en)
|
2001-06-21 |
2004-03-30 |
Ariad Pharmaceuticals, Inc. |
Quinolinones and uses thereof
|
|
US6740757B2
(en)
*
|
2001-08-29 |
2004-05-25 |
Pfizer Inc |
Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
|
|
AU2002358677B2
(en)
|
2001-12-19 |
2008-02-07 |
Janssen Pharmaceutica N.V. |
1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
|
|
ATE364384T1
(de)
|
2002-03-22 |
2007-07-15 |
Janssen Pharmaceutica Nv |
Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
|
|
EP1497295B1
(en)
|
2002-04-15 |
2006-08-16 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
|
|
SI1585743T1
(sl)
*
|
2002-12-19 |
2007-08-31 |
Pfizer |
Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni
|
|
CA2546727C
(en)
|
2003-11-20 |
2012-10-02 |
Children's Hospital Medical Center |
Gtpase inhibitors and methods of use
|
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
JP2008510792A
(ja)
*
|
2004-08-26 |
2008-04-10 |
ファイザー・インク |
タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
|
|
SI1784396T1
(sl)
*
|
2004-08-26 |
2011-03-31 |
Pfizer |
S pirazolom substituirane aminoheteroarilne spojine kot zaviralci protein-kinaze
|
|
PL1786785T3
(pl)
*
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
|
|
ME01509B
(me)
|
2004-11-05 |
2014-04-20 |
Janssen Pharmaceutica Nv |
Terapeutska upotreba inhibitora farneziltransferaze i postupci praćenja njihove efikasnosti
|
|
US20060107555A1
(en)
*
|
2004-11-09 |
2006-05-25 |
Curtis Marc D |
Universal snow plow adapter
|
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
|
JP2009508809A
(ja)
|
2005-07-29 |
2009-03-05 |
チルドレンズ ホスピタル メディカル センター |
ＲＡＣ−１ＧＴＰａｓｅのＧＴＰａｓｅ阻害因子とその使用方法およびその結晶構造
|
|
CN101517068B
(zh)
|
2005-09-07 |
2017-02-08 |
安进弗里蒙特公司 |
活化素受体样激酶‑1的人单克隆抗体
|
|
JP5055284B2
(ja)
|
2005-09-20 |
2012-10-24 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
|
|
JP2009521470A
(ja)
|
2005-12-23 |
2009-06-04 |
リンク メディシン コーポレイション |
シヌクレイン障害の治療
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
|
AU2007240437B2
(en)
|
2006-04-20 |
2012-12-06 |
Janssen Pharmaceutica N.V. |
Heterocyclic compounds as inhibitors of c-fms kinase
|
|
WO2007124319A1
(en)
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
|
MX2008013990A
(es)
|
2006-05-09 |
2009-01-29 |
Pfizer Prod Inc |
Derivados de cicloalquilamino acidos.
|
|
MX2009001715A
(es)
|
2006-08-21 |
2009-02-25 |
Hoffmann La Roche |
Terapia tumoral con un anticuerpo anti-vegf.
|
|
WO2008112525A2
(en)
*
|
2007-03-09 |
2008-09-18 |
Link Medicine Corporation |
Treatment of lysosomal storage diseases
|
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
|
WO2009151683A2
(en)
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
NZ593090A
(en)
|
2008-11-13 |
2013-06-28 |
Link Medicine Corp |
Azaquinolinone derivatives and uses thereof
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
|
PT3385395T
(pt)
|
2015-08-17 |
2020-05-06 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
|
WO2017096165A1
(en)
|
2015-12-03 |
2017-06-08 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
US11124839B2
(en)
|
2016-11-03 |
2021-09-21 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
AU2018225566B2
(en)
|
2017-02-21 |
2019-11-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US11291663B2
(en)
|
2017-08-07 |
2022-04-05 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
KR20210098969A
(ko)
|
2018-11-01 |
2021-08-11 |
쿠라 온콜로지, 인크. |
파네실트랜스퍼라제 저해제를 사용한 암의 치료 방법
|
|
KR20210106513A
(ko)
|
2018-12-21 |
2021-08-30 |
쿠라 온콜로지, 인크. |
편평 세포 암종을 위한 요법
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
|
GB201905721D0
(en)
|
2019-04-24 |
2019-06-05 |
Univ Dundee |
Compounds
|
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
EP4013402B1
(en)
|
2019-08-16 |
2024-11-06 |
Children's Hospital Medical Center |
Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|